These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8615171)

  • 1. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease.
    Chase TN; Engber TM; Mouradian MM
    Adv Neurol; 1996; 69():497-501. PubMed ID: 8615171
    [No Abstract]   [Full Text] [Related]  

  • 2. Striatal molecular mechanisms and motor dysfunction in Parkinson's disease.
    Chase TN; Konitsiotis S; Oh JD
    Adv Neurol; 2001; 86():355-60. PubMed ID: 11553996
    [No Abstract]   [Full Text] [Related]  

  • 3. Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia.
    Riederer P; Lange KW; Kornhuber J; Danielczyk W
    Arzneimittelforschung; 1992 Feb; 42(2A):265-8. PubMed ID: 1350197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuronal networks and synaptic plasticity in Parkinson's disease: beyond motor deficits.
    Calabresi P; Galletti F; Saggese E; Ghiglieri V; Picconi B
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S259-62. PubMed ID: 18267247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mechanisms of motor disorders in Parkinson's disease].
    Yanagisawa N
    No To Shinkei; 1989 Jul; 41(7):647-58. PubMed ID: 2684249
    [No Abstract]   [Full Text] [Related]  

  • 6. Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease.
    Oh JD; Chase TN
    Amino Acids; 2002; 23(1-3):133-9. PubMed ID: 12373527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Risk factors associated with the development of motor complications in Parkinson's disease. A study in a Chilean population].
    Juri-Claveria C; Aguirre-M C; Viviani-G P; Chana-Cuevas P
    Rev Neurol; 2007 Jul 16-31; 45(2):77-80. PubMed ID: 17642046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sleep dysfunction in Parkinson's disease.
    Trenkwalder C
    Clin Neurosci; 1998; 5(2):107-14. PubMed ID: 10785836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
    de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
    Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Stocchi F
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S9-S15. PubMed ID: 19131046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression and bilateralisation of motor signs in Parkinson's disease.
    Cosentino Luis Torres C
    Parkinsonism Relat Disord; 2005 Aug; 11(5):335. PubMed ID: 15886044
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease.
    Wenning GK; Bösch S; Luginger E; Wagner M; Poewe W
    Adv Neurol; 1999; 80():545-8. PubMed ID: 10410769
    [No Abstract]   [Full Text] [Related]  

  • 13. Visual dysfunction in Parkinson's disease.
    Rodnitzky RL
    Clin Neurosci; 1998; 5(2):102-6. PubMed ID: 10785835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of glutamate in the pathophysiology of Parkinson's disease.
    Blandini F; Greenamyre JT; Nappi G
    Funct Neurol; 1996; 11(1):3-15. PubMed ID: 8936453
    [No Abstract]   [Full Text] [Related]  

  • 15. The dopaminergic nigrostriatal system and Parkinson's disease: molecular events in development, disease, and cell death, and new therapeutic strategies.
    Hodaie M; Neimat JS; Lozano AM
    Neurosurgery; 2007 Jan; 60(1):17-28; discussion 28-30. PubMed ID: 17228250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glial cell line-derived neurotrophic factor: a novel therapeutic approach to treat motor dysfunction in Parkinson's disease.
    Lapchak PA; Gash DM; Jiao S; Miller PJ; Hilt D
    Exp Neurol; 1997 Mar; 144(1):29-34. PubMed ID: 9126148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anxiety disorders and Parkinson's disease.
    Iruela LM; Ibañez-Rojo V; Palanca I; Caballero L
    Am J Psychiatry; 1992 May; 149(5):719-20. PubMed ID: 1575281
    [No Abstract]   [Full Text] [Related]  

  • 19. Greater motor improvement in right hemibody Parkinson's patients after dopaminergic medications.
    Foster PS; Drago V; Skidmore F; Skoblar BM; Crucian GP; Heilman KM
    Parkinsonism Relat Disord; 2009 Jan; 15(1):20-3. PubMed ID: 18387842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin, dopamine, and motor effects in Parkinson's disease.
    Miyawaki E; Meah Y; Koller WC
    Clin Neuropharmacol; 1997 Aug; 20(4):300-10. PubMed ID: 9260728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.